The Dual Role of Exosome-Mediated Central-Peripheral Immune Dialogue in Amyotrophic Lateral Sclerosis-Associated Neuroinflammation Authors: Tao Jin, Bingjie Yang, Zhuoyuan Cai, Hao Zhang, Ting Wang Published: 2026 ABSTRACT AbstractObjectiveAmyotrophic lateral sclerosis (ALS) is increasingly viewed as a multisystem disorder in which central–peripheral immune communication may modify neuroinflammation. Exosomes, an endosome-derived subset of extracellular vesicles (EVs), have been proposed as mediators of this communication, but the strength and disease specificity of the evidence require critical evaluation.MethodsPubMed/MEDLINE, Web of Science Core Collection, and Scopus were searched from database inception to July 20, 2026, with supplementary citation tracking through Google Scholar and reference lists. Evidence was categorized as human ALS evidence, ALS-specific cellular or animal evidence, evidence from non-ALS neuroinflammatory models, or review-level background evidence.ResultsHuman studies have identified ALS-associated proteins and altered miRNA profiles in circulating EV-containing preparations, but their cellular origin, direction of transfer, and causal relevance remain uncertain. ALS-specific cellular and animal models support the possibility that EVs participate in intercellular protein transfer and modify glial inflammatory, phagocytic, antioxidant, and trophic responses. Some proposed mechanisms, including miR-216a-5p-mediated microglial regulation, are derived mainly from other neurological injury models and should be considered hypothesis-generating. Single-cell studies further indicate that ALS microglia occupy heterogeneous and overlapping states; therefore, M1/M2 terminology is used only as a simplified descriptive framework. Circulating EV cargo remains under investigation as a biomarker source, whereas the additional value of EV-associated neurofilament light chain and the diagnostic utility of TDP-43, SOD1, or miRNAs require independent validation. Therapeutic evidence remains predominantly preclinical, with only small, early, non-confirmatory human studies.ConclusionEVs may participate in central–peripheral immune communication in ALS, but their causal role, cellular origin, in vivo trafficking, and clinical utility remain incompletely established. Standardized methods and rigorous mechanistic and clinical validation are required before EV-based biomarkers or therapies can be translated into practice.Keywords: amyotrophic lateral sclerosis, ALS, neuroinflammation, exosomes, central-peripheral immune communication, microglia Introduction Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the loss of upper and lower motor neurons, resulting in muscle weakness, paralysis, and death, typically within 2 to 5 years after symptom onset.1,2 Its etiology remains incompletely understood and likely involves a heterogeneous interplay among genetic, epigenetic, and environmental factors.3–5 Research and therapeutic development have historically focused predominantly on central nervous system (CNS) mechanisms, including glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, and impaired protein homeostasis.2,6,7 However, the limited disease-modifying efficacy of CNS-directed therapies has encouraged a broader view of ALS as a multisystem disorder in which peripheral tissues and immune responses may modify CNS pathology. Central-peripheral neuroimmune communication has therefore been increasingly implicated as one component of ALS progression, alongside microglial and astrocytic activation, altered peripheral immune-cell responses, and disruption of the blood–brain and blood–spinal cord barriers.3,8–13 Importantly, ALS is molecularly heterogeneous, and its neuroimmune landscape is unlikely to be uniform across patients or disease subtypes. C9orf72 repeat expansions are associated with both repeat-related toxic gain-of-function mechanisms and reduced physiological C9orf72 activity. Experimental C9orf72 deficiency disrupts endosomal and autophagy–lysosomal homeostasis and alters the functions of macrophages and microglia, supporting a potential link between this genetic subtype and dysregulated innate immunity.14,15 TDP-43 and fused in sarcoma (FUS) are RNA-binding proteins involved in RNA processing, transport, stability, translation, and stress-granule dynamics. Their nuclear depletion, cytoplasmic mislocalization, or aggregation can result in widespread RNA misprocessing and disturbances in proteostasis.16–19 Because RNA-binding proteins participate in selective RNA loading into extracellular vesicles (EVs), while endolysosomal trafficking is integral to exosome biogenesis, abnormalities in RNA metabolism and vesicular trafficking may influence EV cargo selection, release, or biological activity.20–24 Nevertheless, direct ALS-specific evidence linking particular genetic or RNA-processing abnormalities to distinct EV phenotypes remains limited. Different genetic and molecular forms of ALS may therefore be associated with partially distinct immune and EV signatures, which should be considered when interpreting findings across experimental models and patient cohorts. Within this heterogeneous neuroimmune environment, exosomes have emerged as potential mediators of intercellular communication between central and peripheral compartments. Exosomes are commonly described as endosome-derived EVs, generally ranging from approximately 30 to 150 nm in diameter, that transport proteins, lipids, and nucleic acids, including microRNAs.20,21,25–27 Experimental evidence indicates that some EV populations can cross biological barriers, including the blood–brain barrier, although their transport efficiency varies according to cellular source, surface composition, disease state, and experimental conditions.26,28–31 These characteristics suggest that exosomes may participate in bidirectional communication between the peripheral immune system and the CNS, but their causal contribution to ALS progression has not been fully established. This review critically synthesizes current evidence regarding the potential dual roles of exosome-mediated central-peripheral immune communication in ALS-associated neuroinflammation. It examines how EV-associated cargo may contribute to the propagation of inflammatory or pathological signals, while other EV populations may support inflammation-resolving and neuroprotective responses. Particular attention is given to distinguishing findings obtained from patients with ALS and ALS-specific experimental models from mechanisms extrapolated from other neuroinflammatory conditions. The review also evaluates the emerging biomarker and therapeutic potential of exosomes while considering the evidentiary and translational limitations that currently restrict their clinical application. Literature Search and Review Methodology This integrative narrative review was informed by a structured literature search of PubMed/MEDLINE, Web of Science Core Collection, and Scopus from database inception to July 20, 2026. Google Scholar and the reference lists of eligible articles and relevant reviews were used for supplementary citation tracking. The core search combined terms related to amyotrophic lateral sclerosis (ALS; amyotrophic lateral sclerosis OR motor neuron disease), extracellular vesicles (exosome* OR extracellular vesicle* OR small extracellular vesicle* OR microvesicle*), and neuroimmune mechanisms (neuroinflamm* OR microglia* OR astrocyte* OR peripheral immune* OR central-peripheral immune communication OR blood-brain barrier). Targeted searches additionally combined ALS and extracellular vesicle terms with TDP-43, SOD1, C9orf72, FUS, miR-155, miR-146a, Nrf2, mesenchymal stem cell, regulatory T cell, biomarker, and therapy. Boolean operators AND and OR were adapted to the syntax of each database. Eligible publications included peer-reviewed English-language human studies, animal studies, and in vitro investigations examining extracellular vesicle biology, cargo composition, intercellular transfer, immune signaling, biomarker potential, or therapeutic applications in ALS. Reviews and meta-analyses were used to provide background information and identify additional primary studies. Because ALS-specific evidence remains limited for some proposed mechanisms, studies from closely related neuroinflammatory or neurodegenerative models were included only when they provided directly relevant mechanistic context; such findings were identified as indirect or extrapolative evidence. Duplicate reports, conference abstracts without accessible full texts, protocols, editorials, letters without original data, and studies without sufficient relevance to ALS, extracellular vesicles, or neuroimmune communication were excluded. Titles and abstracts were screened for relevance, followed by full-text assessment of potentially eligible articles. Uncertain eligibility decisions were discussed among the authors and resolved by consensus. For evidence synthesis, the included literature was categorized as human ALS evidence, ALS-specific animal or cellular evidence, evidence from non-ALS neuroinflammatory or neurodegenerative models, or review-level and background evidence. Greater interpretive weight was assigned to human and ALS-specific studies, whereas findings from other disease models were used only to contextualize or generate mechanistic hypotheses. Given the integrative narrative design, no formal meta-analysis or quantitative risk-of-bias assessment was performed; however, study design, model relevance, sample scale, and major methodological limitations were considered qualitatively when interpreting the evidence. Biological Basis of EV-Mediated Communication Exosomes are an endosome-derived subset of EVs formed as intraluminal vesicles within multivesicular bodies, which may fuse with lysosomes for degradation or with the plasma membrane to release their vesicular contents.20,21,25 Because direct evidence of endosomal origin is unavailable in many clinical and experimental studies, the broader term EVs is more appropriate when vesicle biogenesis has not been established; exosome should be reserved for preparations with adequate evidence of endosomal origin.32 The key biological properties of EVs and their potential implications for ALS are summarized in Table 1. EV populations differ in cellular source, size, density, membrane composition, surface proteins, and molecular cargo. These characteristics are also influenced by the physiological state of the parent cells and by pre-analytical and analytical procedures.20,21,25,32 Common isolation methods do not recover equivalent vesicle populations. Differential ultracentrifugation may co-isolate lipoproteins and protein aggregates; polymer-based precipitation often provides a high particle yield but retains soluble proteins and other non-vesicular components; size-exclusion chromatography reduces soluble protein contamination but may not distinguish EVs from similarly sized particles; and immunoaffinity capture enriches only marker-positive EV subsets.32–34 Table 1Key Biological Properties of Extracellular Vesicles and Their Potential Implications for ALSFeatureDescriptionPotential Implications for ALSRepresentative LiteratureSizeSmall EVs are commonly reported within an approximate diameter range of 30–150 nm.Nanoscale size may facilitate cellular uptake but does not alone determine BBB transport.[20,25,32]Lipid bilayerCell-derived membrane enclosing or associating with bioactive cargo.May protect selected cargo and support interactions with recipient cells.[20,21]Surface moleculesTetraspanins, adhesion molecules, lipids, and other ligands.Influence cellular recognition and uptake and may be modified experimentally for targeting.[20,35,36]CargoProteins, lipids, messenger RNAs, miRNAs, and other molecules.May transmit disease-associated or regulatory signals between cells.[20,22,26]BBB interactionEndothelial binding, receptor-mediated endocytosis, intracellular trafficking, and transcytosis; paracellular movement may occur when barrier integrity is disrupted.May permit CNS exposure under selected conditions, with efficiency affected by EV properties, inflammation, dose, and administration route.[30,37,38]Abbreviations: ALS, amyotrophic lateral sclerosis; BBB, blood–brain barrier; CNS, central nervous system; EVs, extracellular vesicles; miRNAs, microRNAs. Key Biological Properties of Extracellular Vesicles and Their Potential Implications for ALS Abbreviations: ALS, amyotrophic lateral sclerosis; BBB, blood–brain barrier; CNS, central nervous system; EVs, extracellular vesicles; miRNAs, microRNAs. Lipoproteins, ribonucleoprotein complexes, protein aggregates, and other extracellular particles may overlap with EVs in size or density. Consequently, isolation and purification methods can affect particle counts, microRNA (miRNA) and protein profiles, cellular uptake, and apparent biological activity.32–34 Results obtained from differently prepared EV fractions are therefore not directly interchangeable, and their biological effects cannot always be attributed specifically to purified exosomes. Throughout this review, findings are described as EV-associated rather than exosome-specific when vesicle origin, purity, or subtype identity has not been sufficiently demonstrated. Diverse Bioactive Cargo EVs can transport proteins, lipids, messenger RNAs, and non-coding RNAs. Cargo incorporation is influenced by endosomal sorting pathways, membrane microdomains, RNA-binding proteins, and the physiological or inflammatory state of the parent cell.20–25,35 However, cargo-selection mechanisms remain incompletely characterized, and apparent enrichment may also depend on isolation, normalization, and analytical procedures. EV-associated proteins include membrane receptors, adhesion molecules, enzymes, signaling proteins, and proteins implicated in neurodegenerative pathology.20,22,27 TDP-43 and mutant or misfolded superoxide dismutase 1 (SOD1) have been detected in EV-containing preparations from ALS-related cellular and experimental models, supporting a possible role in protein clearance or intercellular transfer.22,27 These findings do not, however, establish that peripheral EVs routinely transport pathogenic proteins across the BBB or drive protein propagation in patients with ALS. The cellular origin, molecular form, destination, and in vivo significance of EV-associated TDP-43 and SOD1 remain insufficiently defined. EV-associated miRNAs may regulate immune, inflammatory, and cellular stress-response pathways after uptake by recipient cells, although their effects depend on concentration, accompanying cargo, and recipient-cell state.26,39 Circulating small EV studies in ALS have identified altered profiles involving miR-23c, miR-192-5p, miR-146a-5p, and other miRNAs.40–42 These findings support their investigation as candidate biomarkers or mechanistic mediators, but differences in cohort composition, sample processing, EV enrichment, RNA extraction, and normalization limit comparison across studies. EV membrane lipids and surface molecules also influence vesicle stability, cellular recognition, uptake, circulation time, and tissue distribution.20,35 EV cargo profiling may therefore provide information about ALS-associated cellular states and identify candidate biomarkers or therapeutic targets. Interpretation nevertheless requires consideration of EV heterogeneity, contamination, methodological variability, and the limited amount of ALS-specific functional evidence.5,22,23,32,43,44 Transport Across the Blood–Brain Barrier The BBB maintains CNS homeostasis by restricting nonspecific entry of circulating substances, but it also limits the delivery of many therapeutic agents to the brain and spinal cord.28–30 Experimental evidence indicates that selected EV populations can interact with and, under some conditions, traverse BBB models; this is not a universal or equally efficient property of all EVs. Proposed mechanisms include endothelial binding, receptor- or ligand-dependent endocytosis, intracellular trafficking, and transcytosis.30,37 Passive passage through intact endothelial tight junctions is unlikely to be the principal route. Paracellular movement may increase when inflammation or vascular injury compromises barrier integrity, but this differs from regulated transport across an intact BBB.12,30 Moreover, endothelial uptake does not necessarily demonstrate complete passage into the CNS parenchyma, because internalized EVs may be retained, recycled, or degraded. Transport efficiency depends on EV source, size, membrane composition, surface molecules, charge, endothelial-receptor interactions, and recipient disease state.30,37 Inflammation and BBB or blood–spinal cord barrier dysfunction may alter uptake and permeability, although the direction and magnitude of these effects vary across EV populations and experimental conditions.12,37 Quantitative data in patients with ALS remain limited. Administration route and systemic disposition also determine CNS exposure. After intravenous administration, many EVs are rapidly cleared and accumulate in the liver, spleen, and other organs through the mononuclear phagocyte system. CNS delivery therefore depends on dose, circulation time, vesicle source, surface composition, and peripheral sequestration.26,28,31,38,45,46 Intranasal administration may permit access through olfactory, trigeminal, or perivascular pathways, whereas local, intrathecal, or intracerebral administration may increase regional exposure but is more invasive. Experimental pharmacokinetic data confirm that dose and administration route substantially affect EV biodistribution.38 Engineered EVs may be modified through surface ligands, membrane proteins, chemical conjugation, or cargo-loading procedures to improve stability, endothelial interaction, or uptake by selected CNS cell populations.28,36,46–50 However, engineered EVs should not be assumed to share the biodistribution or BBB transport properties of naturally released EVs, because engineering may alter particle composition, aggregation, clearance, immunogenicity, and functional activity. Overall, selected natural or engineered EV populations can enter the CNS under specific experimental conditions. Their transport depends on EV composition, recipient disease state, BBB integrity, engineering strategy, dose, systemic clearance, and administration route. Quantitative evidence for efficient or bidirectional EV transport across the BBB in patients with ALS remains limited; EV-mediated central–peripheral communication should therefore be regarded as biologically plausible rather than an established or uniformly efficient pathway in human ALS. EV-Associated Signals from Peripheral Immune and Stromal Cells Peripheral immune alterations, including changes in monocyte, macrophage, and T-cell phenotypes, have been reported in ALS and may influence the CNS inflammatory environment.3,8,11 Although peripheral immune cells release EVs containing proteins, lipids, and nucleic acids, the cellular origin and biological destination of most circulating EVs have not been resolved in ALS. Evidence from circulating EV preparations, patient-derived cell systems, ALS experimental models, and other inflammatory conditions should therefore not be regarded as equivalent. Available findings suggest that peripheral EV-associated signaling may participate in central–peripheral immune communication, but its contribution to ALS progression remains incompletely established.22,27,29 The proposed pro-inflammatory and counter-regulatory effects are summarized in Table 2. Table 2Comparison of Potential Pro-Inflammatory and Counter-Regulatory EV-Associated Signals in ALSEV-Associated SignalReported or Proposed SourceRepresentative CargoPotential CNS EffectsInterpretation in ALSRepresentative LiteraturePotential pro-inflammatory signalsCirculating EV fractions and ALS-related cellular models; peripheral immune-cell origin is often unresolvedTDP-43, SOD1, miR-155, and other stress- or inflammation-associated moleculesMay promote protein transfer and alter inflammatory, phagocytic, or stress responses in microglia and other CNS cellsA plausible contributor to neuroinflammation, but not an established driver of ALS progression[51–54]Potential counter-regulatory and repair-associated signalsMSCs and TregsmiR-216a-5p, miR-146a-5p, and other regulatory moleculesMay reduce astrocyte activation, oxidative stress, and inflammatory signaling and support trophic or repair-associated responsesPredominantly supported by cellular and animal studies; effects are source-, preparation-, dose-, and context-dependent[40,55–61]Notes: M1-like and M2-like terminology represents a simplified descriptive framework. Microglial states are heterogeneous and dynamic, and MSC-derived EVs do not uniformly induce a stable M2 phenotype.Abbreviations: ALS, amyotrophic lateral sclerosis; CNS, central nervous system; EVs, extracellular vesicles; MSCs, mesenchymal stem/stromal cells; Tregs, regulatory T cells; TDP-43, TAR DNA-binding protein 43; SOD1, superoxide dismutase 1; miR, microRNA. Comparison of Potential Pro-Inflammatory and Counter-Regulatory EV-Associated Signals in ALS Notes: M1-like and M2-like terminology represents a simplified descriptive framework. Microglial states are heterogeneous and dynamic, and MSC-derived EVs do not uniformly induce a stable M2 phenotype. Abbreviations: ALS, amyotrophic lateral sclerosis; CNS, central nervous system; EVs, extracellular vesicles; MSCs, mesenchymal stem/stromal cells; Tregs, regulatory T cells; TDP-43, TAR DNA-binding protein 43; SOD1, superoxide dismutase 1; miR, microRNA. Potential Pro-Inflammatory Signals Although peripheral immune phenotypes are altered in ALS,3,8,11 direct characterization of EVs derived specifically from peripheral monocytes, macrophages, or T cells remains limited. Most circulating EV studies have not established vesicle parent cells, and the detection of potentially pathogenic cargo in plasma EV fractions does not demonstrate peripheral immune-cell origin, BBB transport, or delivery to specific CNS cells. TDP-43, phosphorylated TDP-43, SOD1, and FUS have been detected at increased levels in plasma-derived microvesicle preparations from patients with sporadic ALS.51 This finding links circulating EV-containing fractions to ALS-associated proteins but does not establish their cellular origin or direction of transport. In a patient-derived cellular model, pathological TDP-43 released by lymphoblastoid cells was detected extracellularly and appeared capable of reaching recipient cells, with EVs identified as one possible transport route.52 Other intercellular transport mechanisms may also have contributed in this in vitro system. ALS-related cellular models provide additional evidence that mutant SOD1 can be transferred through extracellular vesicular and non-vesicular fractions. EVs released by mutant SOD1-expressing motor neuron-like cells were internalized by microglia and altered inflammatory, phagocytic, and senescence-associated markers.53 The response included concurrent pro-inflammatory and counter-regulatory features rather than a uniformly harmful phenotype. These findings support a possible role for EVs in intercellular protein transfer but do not demonstrate that peripheral immune cell-derived EVs carry TDP-43 or SOD1 across the BBB, seed protein aggregation in the human CNS, or independently drive ALS progression. MiR-155 further illustrates the distinction between ALS-associated immune regulation and EV-mediated delivery. Increased miR-155 expression has been observed in ALS spinal cord tissue and SOD1-related rodent models, while experimental inhibition of miR-155 prolonged disease duration and survival in SOD1G93A mice.54 These findings implicate miR-155 in ALS-related inflammatory regulation but do not identify EVs as its relevant delivery mechanism or demonstrate that peripheral EV-associated miR-155 induces a specific microglial state in patients. Circulating small EV studies have also identified altered profiles involving miR-23c, miR-192-5p, and other immune- or stress-related miRNAs in ALS.41,42 These observational findings do not establish vesicle origin, direction of transfer, or functional effects within the CNS. Some miRNAs may represent biomarkers of cellular stress or systemic immune alteration rather than direct mediators of neuroinflammation. Overall, EV-containing preparations from patients with ALS are associated with disease-related proteins and altered miRNA profiles, while cellular models support possible roles in protein transfer and intercellular signaling. However, a continuous causal pathway in which peripheral immune cell-derived EVs enter the CNS and initiate or amplify ALS pathology has not been demonstrated. Peripheral EV-associated pro-inflammatory signaling should therefore be considered plausible but incompletely validated. Potential Anti-Inflammatory and Repair-Associated Signals EVs released by peripheral regulatory and stromal cell populations may exert inflammation-limiting or repair-associated effects. MSCs are a major candidate source, although the composition and biological activity of MSC-derived EVs vary according to tissue source, culture conditions, isolation procedures, dose, and recipient model. Their reported effects should therefore be interpreted within the specific experimental system rather than regarded as a uniform protective property. ALS-specific evidence is derived predominantly from cellular and animal models. MSC-derived EVs reduced pathological astrocyte activation and supported neuronal protection in ALS-related coculture systems, while adipose MSC-derived EVs reduced oxidative stress and modified inflammatory markers in SOD1G93A-expressing microglia.55,56 In SOD1G93A mice, repeated administration of adipose stem cell-derived EVs was associated with improved motor performance, preservation of motor neurons and neuromuscular structures, and reduced glial activation.57 Intranasally administered MSC-derived small EVs were also associated with improved motor function and survival and attenuation of inflammatory and pathological changes in the same transgenic model.58 These findings support preclinical immunomodulatory and neuroprotective effects but do not establish efficacy in genetically and clinically heterogeneous human ALS. The miR-216a-5p mechanism requires a different level of interpretation. EV-mediated delivery of miR-216a-5p and modulation of TLR4/NF-κB/PI3K/AKT signaling were demonstrated primarily in a traumatic spinal cord injury model, in which hypoxia-preconditioned MSC-derived EVs altered simplified M1/M2-associated markers and promoted functional recovery.59 This pathway provides mechanistic context but has not been directly demonstrated as an EV-mediated mechanism in ALS. Tregs represent another potential source of immunoregulatory EVs. Alterations in Treg abundance and suppressive function have been associated with ALS progression.60 An ALS patient study separately identified dysregulated EV-associated miR-146a-5p and reported an association between higher levels and longer survival, although its cellular origin and protective mechanism remain uncertain.40 In non-ALS human T-cell experiments, Treg-derived EVs were enriched in miR-146a-5p, inhibited CD4+ T-cell proliferation, and reduced STAT1 and IRAK2 expression.61 Direct transfer of Treg-derived EV-associated miR-146a-5p to CNS cells in ALS has not been demonstrated. Human therapeutic evidence remains preliminary. An uncontrolled report described intranasal administration of an exosome-rich MSC secretome in a small mixed-diagnosis cohort that included patients with ALS.62 The small sample, absence of a concurrent control group, heterogeneous diagnoses, repeated treatments in some participants, and non-randomized design preclude conclusions regarding efficacy, disease modification, or CNS immunomodulatory mechanisms. Collectively, MSC- and Treg-associated EV signaling may contribute to inflammation-limiting or repair-associated responses. The strongest ALS-specific evidence comes from cellular systems and SOD1-based animal models, whereas several individual miRNA mechanisms are extrapolated from other inflammatory or injury models. Human evidence remains insufficient to establish therapeutic efficacy, long-term safety, optimal administration strategies, or the specific contribution of EV cargo. CNS Cellular Responses and Microglial State Heterogeneity EVs entering the CNS or released locally by neurons and glial cells may interact with microglia, astrocytes, and neurons. The resulting responses depend on EV source and composition, recipient-cell receptors and uptake pathways, and the local inflammatory and metabolic environment. Microglia are particularly relevant because they integrate tissue-surveillance, phagocytic, metabolic, inflammatory, and neuronal-support functions, but their responses cannot be adequately represented by a stable binary polarization model. The conventional M1/M2 framework was derived largely from experimentally polarized macrophages and later applied to microglia as a simplified descriptive model. In ALS, microglia do not consistently segregate into mutually exclusive M1 and M2 populations. Single-cell and single-nucleus transcriptomic studies instead identify overlapping and transitional homeostatic, interferon-responsive, inflammatory, phagocytic, lipid-metabolic, proliferative, and stress-associated states.63–67 These programs may coexist within individual cells and vary according to disease stage, anatomical region, genetic background, sex, and the surrounding cellular environment. Human ALS profiling has identified marked microglial heterogeneity in the motor cortex and spinal cord, including relatively undifferentiated, interferon-responsive, and potentially counter-regulatory populations.64 Human and experimental studies have also identified RIPK1-associated inflammatory glial states that cannot be adequately classified as uniformly M1 or M2.66,67 Disease-associated microglia provide a further example: DAM-like states emerged predominantly after motor neuron degeneration in SOD1G93A mice and changed with disease progression, while related signatures have been reported in human ALS tissues.63,65 DAM should therefore not be interpreted as a single uniformly harmful or protective phenotype. Accordingly, M1-like and M2-like are used below only as conceptual shorthand for predominantly pro-inflammatory or inflammation-resolving features reported in earlier studies. They do not denote stable, mutually exclusive, or fully defined microglial phenotypes. Figure 1 and Table 3 should be interpreted within this spectrum-based framework. Conceptual framework of EV-associated microglial response states in ALS. Potential pro-inflammatory and counter-regulatory EV-associated signals may influence heterogeneous microglial response programs rather than inducing two stable and mutually exclusive phenotypes. M1-like and M2-like states are shown only as simplified descriptors at predominantly pro-inflammatory and inflammation-resolving ends of a dynamic spectrum. Intermediate and overlapping states include interferon-responsive, phagocytic, disease-associated microglia-like, and RIPK1-associated programs. The functional consequences of these responses depend on EV cargo, recipient-cell state, disease stage, anatomical context, and the surrounding cellular environment. Solid arrows indicate ALS-specific preclinical evidence, dashed arrows indicate evidence extrapolated from other neurological models, and dotted arrows indicate limited human or hypothesis-generating evidence. The pathways and outcomes shown are conceptual and should not be interpreted as deterministic or as established causal mechanisms in human ALS. Abbreviations: ALS, amyotrophic lateral sclerosis; DAM, disease-associated microglia; EVs, extracellular vesicles; IL, interleukin; miR, microRNA; NF-κB, nuclear factor kappa B; NLRP3, NOD-like receptor family pyrin domain-containing 3; PI3K/AKT, phosphoinositide 3-kinase/protein kinase B; RIPK1, receptor-interacting serine/threonine-protein kinase 1; ROS, reactive oxygen species; SOD1, superoxide dismutase 1; TDP-43, TAR DNA-binding protein 43; TNF-α, tumor necrosis factor-alpha. Table 3Conceptual Microglial Response Patterns in ALS and Their Potential Modulation by EV-Associated SignalsMicroglial Response PatternRepresentative FeaturesPotential EV-Associated SignalsPotential Functional Consequences in ALSRepresentative LiteratureM1-like or predominantly pro-inflammatoryIncreased inflammatory cytokine, chemokine, oxidative-stress, and innate immune signaling; phagocytic activity may coexistALS-associated proteins such as TDP-43 or SOD1 and inflammatory regulators such as miR-155May amplify inflammatory and oxidative stress responses, but effects are disease-stage- and context-dependent rather than uniformly neurotoxic[3,12,22,53,54]M2-like or inflammation-resolving and repair-associatedAnti-inflammatory, antioxidant, trophic, and debris-clearance responsesMSC- or Treg-associated EV cargo, including miR-216a-5p and miR-146a-5pMay reduce glial activation and support neuronal survival in selected preclinical models, but does not represent a uniformly protective or stable phenotype[40,55–61]Overlapping and disease-associated statesHomeostatic, interferon-responsive, phagocytic, lipid-metabolic, proliferative, DAM-like, and RIPK1-associated programsSpecific EV contributions remain insufficiently definedFunctional effects may vary across disease stage, anatomical region, genotype, and cellular environment[63–67]Notes: M1-like and M2-like terms are used only as simplified conceptual descriptors. ALS microglia occupy heterogeneous, overlapping, and dynamic states rather than two mutually exclusive phenotypes; individual markers or cytokines should not be interpreted as defining a complete functional state.Abbreviations: ALS, amyotrophic lateral sclerosis; DAM, disease-associated microglia; EVs, extracellular vesicles; MSCs, mesenchymal stem/stromal cells; SOD1, superoxide dismutase 1; TDP-43, TAR DNA-binding protein 43; Tregs, regulatory T cells. Conceptual Microglial Response Patterns in ALS and Their Potential Modulation by EV-Associated Signals Notes: M1-like and M2-like terms are used only as simplified conceptual descriptors. ALS microglia occupy heterogeneous, overlapping, and dynamic states rather than two mutually exclusive phenotypes; individual markers or cytokines should not be interpreted as defining a complete functional state. Abbreviations: ALS, amyotrophic lateral sclerosis; DAM, disease-associated microglia; EVs, extracellular vesicles; MSCs, mesenchymal stem/stromal cells; SOD1, superoxide dismutase 1; TDP-43, TAR DNA-binding protein 43; Tregs, regulatory T cells. Cellular Recognition and Internalization EV-mediated signaling involves surface interaction, internalization, or membrane fusion. EV tetraspanins, adhesion molecules, lipids, and other ligands may interact with receptors on recipient cells.20,21,35 Uptake may occur through clathrin- or caveolin-associated endocytosis, macropinocytosis, phagocytosis, or direct membrane interaction, influencing whether cargo is released, recycled, retained within endosomes, or degraded. Microglia and astrocytes can internalize EVs released by CNS cells or introduced experimentally, although uptake varies with EV source, surface composition, concentration, and recipient-cell state.13,68 In an ALS-related cellular model, EVs released from mutant SOD1-expressing motor neuron-like cells were internalized by microglia and altered inflammatory, phagocytic, and senescence-associated markers.53 The resulting response contained both pro-inflammatory and counter-regulatory features rather than a single polarized state. Evidence that endogenous peripheral EVs selectively target microglia in patients with ALS remains limited. EV uptake in experimental models does not establish peripheral origin, transport route, or functional relevance in human disease, and engineered targeting findings should not be extrapolated directly to naturally circulating EV populations. EV-Associated Pro-Inflammatory Microglial Responses EV-associated proteins, miRNAs, lipids, and other components may influence stress-response and innate immune pathways in recipient microglia. EV-associated mutant SOD1 can be internalized by microglia and modify inflammatory and phagocytic functions in ALS-related cellular systems.53 However, the response is not exclusively pro-inflammatory, and evidence that EV-associated TDP-43 directly activates defined inflammatory pathways in ALS microglia remains limited.22,27 Inflammatory EV-associated signals may affect NF-κB-related pathways and cytokine or chemokine expression, but the detection of TNF-α, IL-1β, IL-6, or similar mediators does not establish a complete M1 phenotype. Single-cell studies demonstrate that inflammatory expression can coexist with phagocytic, metabolic, interferon-responsive, and stress-adaptive programs.64–67 RIPK1-regulated inflammatory microglial and glial states have been identified in ALS models and human spinal cord tissue, although they have not been shown to arise specifically from EV exposure.66,67 MiR-155 further illustrates the distinction between ALS-associated inflammatory regulation and EV-mediated signaling. Increased miR-155 expression has been reported in ALS tissues and experimental models, and its inhibition prolonged disease duration and survival in SOD1G93A mice.54 These findings do not demonstrate that peripheral EV-associated miR-155 enters the CNS or induces a discrete pro-inflammatory microglial state. Overall, EV-associated signals may contribute to inflammatory microglial responses, but their direction and magnitude are context-dependent and should not be equated with uniform neurotoxicity. EV-Associated Inflammation-Resolving and Reparative Responses EVs may also induce inflammation-limiting, antioxidant, phagocytic, or trophic programs. In ALS-related cellular models, MSC-derived EVs reduced pathological astrocyte activation and oxidative stress and modified microglial inflammatory features.55,56 In SOD1G93A mice, MSC- or adipose stem cell-derived EV administration was associated with reduced glial activation, motor-neuron and neuromuscular preservation, improved motor performance, and prolonged survival in some experimental settings.57,58 These findings do not establish conversion to a stable or uniformly protective M2 phenotype. The miR-216a-5p–TLR4/NF-κB/PI3K/AKT mechanism was demonstrated primarily in a traumatic spinal cord injury model rather than ALS.59 Its effects on simplified M1/M2-associated markers provide mechanistic context but remain hypothesis-generating in ALS. Similarly, EV-associated miR-146a-5p has been associated observationally with ALS survival, while Treg-derived EVs containing miR-146a-5p demonstrated immunoregulatory effects in non-ALS T-cell systems.40,61 Direct transfer of Treg-derived EV-associated miR-146a-5p to CNS cells in ALS has not been demonstrated. In ALS-related astrocyte models, MSC-derived EVs increased Nrf2 nuclear localization or expression and reduced oxidative stress.55 This supports EV-associated modulation of antioxidant pathways in vitro but does not establish Nrf2 activation in microglia, induction of an M2-like state, or clinically relevant neuroprotection. EV-based manipulation of Nrf2 therefore remains an investigational mechanism.69 Taken together, EV-associated inflammation-resolving responses are supported mainly by cellular and animal studies. Their effects depend on EV preparation, cargo, recipient cell, anatomical context, and disease stage and should not be interpreted as evidence of a homogeneous protective microglial population. Functional Consequences of EV-Associated Neuroimmune Signaling EV-associated communication may modify glial stress responses, neuron–glia interactions, and central–peripheral immune feedback in ALS. Its functional consequences are likely to depend on EV source and composition, recipient-cell state, anatomical location, disease stage, and the surrounding inflammatory and metabolic environment. Current evidence does not establish EVs as independent determinants of disease progression.3,22,64–67 Potential Contributions to Neurodegenerative Progression Persistent inflammatory and stress-associated glial responses may increase motor-neuron vulnerability through oxidative stress, excitotoxicity, mitochondrial and endoplasmic reticulum dysfunction, impaired trophic support, and altered synaptic homeostasis.3,6–8,12,17 EV-associated signals may reinforce some of these processes after uptake by neurons or glial cells, as suggested by ALS-related cellular models, but their contribution to neurodegeneration has not been quantified in patients.22,53 The effects of EV exposure are unlikely to correspond to a uniformly harmful microglial state. As discussed above, inflammatory, interferon-responsive, phagocytic, metabolic, proliferative, and stress-associated programs may coexist and vary with disease stage and anatomical region.63–67 Inflammatory signaling or phagocytic activity may therefore have different consequences depending on timing, cellular context, and the material being cleared. Neuronal and glial injury may increase local inflammatory signaling and EV release, potentially creating feedback between tissue damage and immune activation. However, a continuous causal sequence in which peripheral EVs enter the CNS, induce a defined microglial state, and accelerate clinical progression has not been demonstrated.3,8,12,22 Peripheral immune abnormalities, including altered RNA regulation, may further modify the systemic inflammatory environment, but their relationship to EV composition and CNS outcomes remains unclear.8,70 EV-associated signaling should therefore be regarded as a potential modifier within a broader neurodegenerative network rather than a confirmed primary driver of ALS progression. Potential Counter-Regulatory and Repair-Associated Effects EV-associated signaling may also support inflammation-limiting, antioxidant, phagocytic, or trophic responses. In ALS-related cellular models, MSC-derived EVs reduced pathological astrocyte activation and oxidative stress and modified microglial inflammatory and phagocytic features.53,55,56 In SOD1G93A mice, stem cell-derived EV preparations were associated with reduced glial activation, preservation of motor neurons and neuromuscular structures, improved motor performance, and prolonged survival in some experimental settings.57,58 These findings demonstrate functionally favorable effects in selected preclinical systems but do not establish a stable protective microglial phenotype or endogenous repair in patients. Phagocytosis, inflammatory suppression, and trophic signaling may be beneficial in one disease phase but ineffective or potentially detrimental in another, depending on anatomical compartment, recipient-cell state, and the magnitude and persistence of the response.64–67 Protective and detrimental effects may therefore coexist within the same EV preparation or change during disease progression. Their net effect is likely to depend on cargo composition, dose, target-cell availability, and tissue environment. Human evidence remains insufficient to determine whether endogenous EV-associated counter-regulatory responses meaningfully slow ALS progression. Therapeutic products and administration strategies are considered separately in Therapeutic Outlook and Translational Barriers. Potential Bidirectional Communication and the Gut–Brain Interface EV-mediated communication between central and peripheral compartments may occur in both directions, although direct evidence in ALS remains limited. Neurons, astrocytes, and microglia release EVs whose cargo may reflect their physiological or pathological state, and increased IL-6 has been detected in astrocyte-derived EV preparations from patients with sporadic ALS.23,68,71 However, the detection of CNS-associated cargo in peripheral EV preparations does not establish quantitatively meaningful transport across the BBB or modification of systemic immune responses.30,37 Gut microbiota alterations and gut–brain immune interactions have also been reported in ALS.72–75 Nevertheless, the proposed involvement of EVs released by gut-associated immune cells or microorganisms is supported mainly by general intestinal neuroimmune biology and broader peripheral EV research rather than direct ALS-specific evidence.29,76,77 Gut-derived EV signaling should therefore be regarded as an emerging hypothesis rather than an established exosome-mediated feedback loop in ALS. Translational and Diagnostic Perspectives Available evidence supports further investigation of EVs as potential mediators, biomarkers, and delivery platforms in ALS. However, neither their causal contribution to disease progression nor their clinical utility has been established. Translation requires a clear distinction among cellular experiments, animal models, exploratory human studies, and clinically validated applications. Therapeutic Outlook and Translational Barriers Current therapeutic evidence is derived predominantly from in vitro studies and SOD1-based animal models. MSC-derived EV preparations have demonstrated immunomodulatory, antioxidant, and neuroprotective effects in ALS-related cellular systems, while selected animal studies have reported reduced glial activation, motor-neuron preservation, improved motor performance, or prolonged survival.55–58 Human evidence is substantially more limited. One pilot study administered two intravenous infusions of bone marrow MSC-derived EVs to ten patients with ALS and followed them for three months, while an uncontrolled report examined an intranasally administered exosome-rich secretome in a small mixed-diagnosis population.62,78 These studies provide preliminary safety observations but do not establish clinical efficacy, disease modification, or superiority over standard care. Naturally derived and engineered EVs are being investigated as therapeutic products. Engineering approaches include parent-cell modification, post-isolation cargo loading, and surface functionalization intended to alter stability, targeting, or cellular uptake.36,46–50 Evidence that these strategies achieve selective and therapeutically relevant delivery to motor neurons, astrocytes, or defined microglial states in ALS remains preclinical. Engineered products may also differ from endogenous EVs in composition, biodistribution, clearance, and biological activity. Several clinical questions remain unresolved. No adequately powered randomized trial has established the efficacy of an EV-based intervention in ALS, and available studies do not define long-term safety, optimal dose, dose-normalization method, administration route, treatment interval, or duration of repeated dosing. Pharmacokinetic and tissue-distribution data are also limited. Following systemic administration, substantial EV uptake may occur in the liver, spleen, and other peripheral organs, while CNS exposure varies with vesicle source, surface composition, dose, and administration route.26,28,38,46 Successful delivery in cellular or animal models therefore cannot be assumed to produce reproducible CNS exposure in patients. Product development introduces additional variability. Donor characteristics, tissue source, cell passage, culture medium, oxygen conditions, inflammatory preconditioning, harvest interval, and purification method may influence EV yield, subtype composition, and cargo.20,21,32,79,80 Cargo-loading procedures require quantitative assessment of loading and encapsulation efficiency, cargo integrity, vesicle damage, release kinetics, and removal of unencapsulated drugs, nucleic acids, or proteins. Suitable experimental controls should include unloaded EVs and equivalent concentrations of free cargo.32,36,46–50 Storage and handling may alter particle concentration, aggregation, membrane integrity, cargo content, uptake, and functional potency. These effects depend on storage medium, temperature, duration, container material, and freeze–thaw cycles, and may differ between loaded and unloaded products.81,82 Product comparability therefore cannot be based solely on particle count or conventional surface markers. Reproducible manufacturing requires validated identity, purity, content, and mechanism-relevant potency assays with predefined criteria for batch-to-batch consistency.32,79,83 Safety assessment must extend beyond short-term tolerability. Non-specific tissue uptake may produce unintended immune or metabolic effects, and EV activity may vary from anti-inflammatory to pro-inflammatory according to parent cell and manufacturing conditions. Some EV populations expose phosphatidylserine or tissue factor-associated activity and may have procoagulant potential, although this risk cannot be generalized to all products.79,84 Engineered surface ligands or membrane modifications may also affect aggregation, complement interaction, immunogenicity, clearance, and long-term toxicity. These properties require product-specific single- and repeated-dose evaluation. Clinical-grade development should follow good manufacturing practice (GMP) standards and define the product by its source, manufacturing process, EV-enrichment method, composition, intended mechanism, and potency. Release criteria should address identity, particle and protein characteristics, purity, residual contaminants, sterility, endotoxin, mycoplasma, adventitious agents, stability, and functional activity.32,79,80,83 Scalable production must also demonstrate lot-to-lot comparability after changes in cell expansion, purification, storage, or manufacturing site. Until these clinical, manufacturing, safety, and regulatory requirements are addressed, EV-based treatment for ALS should remain investigational. Diagnostic Potential and Validation Requirements Circulating EVs provide access to proteins and nucleic acids associated with ALS-related cellular changes, but they should currently be regarded as sources of candidate biomarkers rather than established liquid-biopsy tools. The cellular origin of most circulating EVs is uncertain, and detection of CNS-related cargo does not necessarily demonstrate BBB passage or origin from a specific CNS cell population.22,23,30,32 Neurofilament light chain (NfL) is an established marker of axonal injury when measured in plasma, serum, or cerebrospinal fluid and has demonstrated diagnostic, prognostic, and pharmacodynamic relevance in ALS.44,85,86 In contrast, whether EV-associated NfL provides additional cellular-source specificity, analytical sensitivity, or clinical value beyond conventional fluid NfL remains unproven. Circulating EV studies have identified differences in miR-23c, miR-192-5p, miR-146a-5p, and other miRNAs between patients with ALS and controls.40–42 These findings support continued biomarker investigation, but reported profiles are affected by biological-fluid selection, blood-cell and platelet contamination, EV isolation, RNA extraction, normalization strategy, cohort size, disease stage, and treatment status.32,34,41,42 Associations with survival or disease severity require replication in prospectively defined and independently recruited cohorts. ALS-associated proteins, including TDP-43 and SOD1, have been detected in circulating EV-containing fractions, while increased IL-6 has been reported in astrocyte-enriched EV preparations from patients with sporadic ALS.22,51,71 These observations provide proof-of-concept evidence but do not constitute standardized diagnostic tests. Relevant limitations include uncertain vesicle purity, incomplete validation of cell-of-origin enrichment, differences in antibody specificity, low analyte abundance, and the absence of reproducible clinical thresholds. Advanced separation and detection platforms may improve analytical sensitivity and enable higher-resolution analysis of EV subpopulations and cargo.87 However, improved detection does not itself establish clinical utility. Candidate EV biomarkers require harmonized pre-analytical procedures, analytical reproducibility, predefined thresholds, longitudinal assessment, external validation, and demonstration of incremental value beyond established biomarkers and clinical measures. Diagnostic, prognostic, disease-monitoring, and treatment-response applications require separate validation. Table 4 should therefore present these markers as investigational candidates rather than clinically available biomarkers. Table 4Candidate EV-Associated Biomarkers for ALS and Their Current Validation StatusBiomarker TypeCandidate BiomarkerPotential Clinical RelevanceCurrent Status and LimitationsRepresentative LiteratureProteinNfLAxonal injury, disease progression, and prognosisValidated in plasma, serum, and cerebrospinal fluid; exploratory in EV fractions. The incremental value and cellular-source specificity of EV-associated NfL remain unproven.[44,85,86]ProteinTDP-43 and SOD1ALS-associated proteinopathyExploratory. Detected in EV-containing fractions, but vesicle purity, cellular origin, assay standardization, and diagnostic thresholds remain unresolved.[22,51]Inflammatory proteinIL-6Astrocyte-associated inflammatory activityExploratory. Reported in astrocyte-enriched EV preparations from sporadic ALS, but requires independent replication and validation of cell-of-origin enrichment.[71]miRNAmiR-146a-5pPotential prognostic association, including survivalEmerging. Supported by an ALS EV study, but requires prospective external validation and standardized isolation and normalization procedures.[40]miRNAmiR-23c and miR-192-5pPotential diagnostic or disease-associated signaturesEmerging. Differential expression has been reported, but findings are cohort- and method-dependent and lack validated clinical thresholds.[41,42]Notes: No EV-associated biomarker is currently validated for routine ALS diagnosis, prognosis, or treatment monitoring. Diagnostic, prognostic, and pharmacodynamic applications require separate validation in independent prospective cohorts.Abbreviations: ALS, amyotrophic lateral sclerosis; EVs, extracellular vesicles; IL-6, interleukin-6; miRNA, microRNA; NfL, neurofilament light chain; SOD1, superoxide dismutase 1; TDP-43, TAR DNA-binding protein 43. Candidate EV-Associated Biomarkers for ALS and Their Current Validation Status Notes: No EV-associated biomarker is currently validated for routine ALS diagnosis, prognosis, or treatment monitoring. Diagnostic, prognostic, and pharmacodynamic applications require separate validation in independent prospective cohorts. Abbreviations: ALS, amyotrophic lateral sclerosis; EVs, extracellular vesicles; IL-6, interleukin-6; miRNA, microRNA; NfL, neurofilament light chain; SOD1, superoxide dismutase 1; TDP-43, TAR DNA-binding protein 43. Future Research Priorities Future mechanistic studies should identify the cellular source, recipient cell, direction of transfer, and functional consequences of ALS-associated EV populations. This will require source-resolved isolation strategies, matched central and peripheral biospecimens, and integration of EV proteomic, lipidomic, transcriptomic, and surface-marker data. Analyses should account for genotype, molecular subtype, disease stage, anatomical compartment, treatment exposure, age, and sex rather than treating ALS as biologically uniform.5,32,43 Therapeutic development should proceed through standardized, mechanism-informed preclinical programs incorporating dose–response and repeated-dose studies, quantitative biodistribution, pharmacokinetics, CNS target engagement, peripheral-organ exposure, immunogenicity, coagulation assessment, long-term toxicity, and unloaded-EV and free-cargo controls.32,38,79,80 Advancement to human studies should require a defined product, reproducible manufacturing, validated potency assays, and prespecified pharmacodynamic outcomes linked to the proposed mechanism. Biomarker studies should prioritize prospective multicenter cohorts, harmonized sample collection and processing, blinded analysis, and external validation. Candidate EV markers should be compared directly with NfL, clinical progression measures, genotype, and other established prognostic factors. Longitudinal sampling is required to determine whether EV profiles reflect stable disease subtypes, dynamic disease activity, treatment response, or non-specific cellular injury. The immediate objective should be to establish which EV populations can be measured or manufactured reproducibly, what biological information they provide, and whether they add clinically meaningful value beyond existing approaches. Conclusion Current evidence from patient-derived EV analyses and ALS-specific cellular and animal models supports the possibility that EV-associated cargo participates in central–peripheral immune communication and modifies glial and neuronal responses. However, these findings do not establish EVs as independent drivers of ALS progression, and potentially detrimental and counter-regulatory effects may coexist within heterogeneous EV populations. The cellular origin, direction and magnitude of in vivo transfer, BBB transport efficiency, and functional consequences across different genetic backgrounds, anatomical regions, and microglial states remain incompletely defined. Likewise, candidate EV biomarkers and therapeutic products require standardized isolation and characterization, independent clinical validation, reproducible manufacturing, long-term safety assessment, and adequately powered controlled trials. EV-mediated communication therefore represents an investigational framework for understanding ALS neuroinflammation rather than an established pathological or therapeutic nexus. Funding Statement This study was fund by Medical and Health Technology Project of Hangzhou (grant. Z20260088), Zhejiang Provincial Natural Science Foundation of China under Grant No. ZCLMRY26H0901) and Hangzhou Biomedical and health industry development support science and technology special (grant.2024WJC185). Data Sharing Statement Data sharing is not applicable to this article as no data were created or analysed in this article. Author Contributions Conceptualization: Hao Zhang and Zhuoyuan Cai Data curation:Ting Wang Formal analysis:Ting Wang Funding acquisition:Hao Zhang Investigation: Tao Jin Methodology:Tao Jin Project administration:Tao Jin Resources: Bingjie Yang Software: Bingjie Yang Supervision: Zhuoyuan Cai Validation: Zhuoyuan Cai Visualization:Zhuoyuan Cai Writing – original draft:Tao Jin and Bingjie Yang Writing – review & editing:Hao Zhang, Ting Wang and Zhuoyuan Cai Tao Jin and Bingjie Yang They are the co-first authors, contributed equally to this work.All authors took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declared that they have no conflicts of interest regarding this article. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no data were created or analysed in this article.